Omnicell Inc
$ 37.60
0.19%
16 Apr - close price
- Market Cap 1,709,946,000 USD
- Current Price $ 37.60
- High / Low $ 38.00 / 37.30
- Stock P/E 940.00
- Book Value 27.36
- EPS 0.04
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE N/A %
- 52 Week High 55.00
- 52 Week Low 22.66
About
Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
Analyst Target Price
$57.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-10-29 | 2025-07-31 | 2025-05-06 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 0.4 | 0.51 | 0.45 | 0.26 | 0.6 | 0.56 | 0.51 | 0.03 | 0.33 | 0.62 | 0.57 | 0.39 |
| Estimated EPS | 0.4963 | 0.36 | 0.27 | 0.2 | 0.58 | 0.42 | 0.14 | -0.09 | 0.15 | 0.47 | 0.28 | 0.07 |
| Surprise | -0.0963 | 0.15 | 0.18 | 0.06 | 0.02 | 0.14 | 0.37 | 0.12 | 0.18 | 0.15 | 0.29 | 0.32 |
| Surprise Percentage | -19.4036% | 41.6667% | 66.6667% | 30% | 3.4483% | 33.3333% | 264.2857% | 133.3333% | 120% | 31.9149% | 103.5714% | 457.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMCL
2026-04-16 12:40:06
Worldwide Market Reports has released an in-depth study on the "AI Pharmacy Automation Market Size and Forecast 2026-2033," providing a comprehensive analysis of the global market landscape. The report offers data-driven evaluations of historical trends and future projections for revenue and volume, highlighting growth drivers, opportunities, risks, and challenges. It includes SWOT analysis, Porter's Five Forces framework, and detailed breakdowns of regional performance and segment opportunities to aid strategic decision-making for key players like McKesson Corporation, Omnicell, and ScriptPro.
2026-04-15 19:40:06
This article reviews the Q4 performance of several healthcare technology companies, focusing on Omnicell (OMCL) for its weakest performance despite solid overall financial results. It also highlights Privia Health (PRVA) for its strong Q4, Astrana Health (ASTH) for fast revenue growth, and Evolent Health (EVH) for a strong quarter with in-line revenue. The piece concludes with a brief market update, noting shifts from AI concerns to geopolitical risks and encouraging investment in companies with strong fundamentals.
2026-04-14 19:40:06
This article announces an SEC ARS filing by Omnicell, Inc. (OMCL). The filing, dated April 13, 2026, has a low impact and neutral sentiment according to StockTitan. The document is available in PDF format and provides an overview of Omnicell's recent news, SEC filings, and stock data.
2026-04-14 07:09:44
Omnicell, Inc. (Nasdaq:OMCL) will release its first quarter 2026 financial results before market open on Tuesday, April 28, 2026. The company will host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day. Interested parties can dial in or access the webcast via Omnicell's Investor Relations website.
2026-04-13 20:40:13
Omnicell, Inc. (Nasdaq:OMCL) announced it will release its first quarter 2026 financial results before market open on Tuesday, April 28, 2026. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these results. Interested parties can access the call via phone or through the Investor Relations section of Omnicell’s website.
2026-04-13 19:09:44
Omnicell (NASDAQ: OMCL) is holding its 2026 annual meeting on May 19, 2026, where stockholders will vote on several key proposals. These proposals include the election of three Class I directors, an advisory "say-on-pay" vote for executive compensation, an amendment to the 2009 Equity Incentive Plan to add 1.6 million shares, and a change to the company's Certificate of Incorporation to provide exculpation from personal liability for certain officers. Stockholders will also vote on ratifying Deloitte & Touche LLP as the independent auditor for 2026.
